GHK-Cu

GHK-Cu is a copper-binding tripeptide, a small peptide complexed with copper, studied for its role in skin, connective-tissue and cellular renewal. It has been investigated in research on collagen, elastin, skin and follicle support. Because of its tissue-recovery profile, it is grouped with both longevity and foundation research compounds. Much of the literature focuses on skin aging, wound repair and cosmetic formulation, including liposome-based delivery systems.

Research describes GHK-Cu as a copper-peptide complex that interacts with fibroblast activity and the remodeling signals associated with skin and connective tissue. It has been studied as a carrier that binds and delivers copper, a cofactor for numerous tissue-remodeling enzymes. It has also been explored in research on fibroblast signaling and the synthesis of collagen and other structural proteins. Reviews have additionally examined gene-expression data linked to its regenerative and protective actions.

Studies have examined GHK-Cu in several areas. In mice, GHK-Cu-liposomes were reported to accelerate scald wound healing by promoting cell proliferation and angiogenesis. Reviews have discussed its potential as an anti-aging peptide and as a topically applied anti-wrinkle peptide, including advantages and problems. Formulation research has evaluated liposomes as carriers for cosmetic application and methods for measuring skin permeation. Recent reviews also discuss it among peptides of interest in orthopaedic and aesthetic research.

Human safety data for GHK-Cu are limited, particularly for subcutaneous administration. The cited studies focus on animal wound models, cell work, gene-expression analyses and cosmetic formulation, and adverse events are not summarized in them. Broader reviews of approved and unapproved peptide therapies discuss safety considerations across this category of compounds, but well-characterized, compound-specific human safety findings for injectable GHK-Cu have not been established in the cited literature.

Research protocols have used 1 to 10 mg per administration by the subcutaneous route, once daily in the morning, in 12-week blocks followed by 4 weeks off. These figures describe what protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference. GHK-Cu is supplied for laboratory research use only.